Present initial clinical data from SUMMIT, a randomized, double-blind, placebo-controlled, global, multicenter, Phase 2 clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis in the second half of 2023. Data will include safety/tolerability and measures of clinical activity. Present updated clinical data from approximately 30 patients in Part 1 of APEX, a global, multicenter Phase 2 clinical trial of bezuclastinib in patients with advanced systemic mastocytosis at a scientific meeting in the second half of 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on COGT:
- Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
- Analysts Say These 2 Stocks Are Their ‘Top Picks’ for the Rest of 2023
- This Top Insider Just Scooped Up Cogent (NASDAQ:COGT) Stock Worth $9.6M
- Cogent Biosciences remains top pick into ‘derisking’ events at Piper Sandler
- Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
